Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial

被引:5
作者
Nicholls, Stephen J. [1 ,2 ]
Nelson, Adam J. [1 ]
机构
[1] South Australian Hlth & Med Res Inst, POB 11060, Adelaide, SA 5001, Australia
[2] Monash Univ, Monash Cardiovasc Res Ctr, Melbourne, Vic, Australia
关键词
ACUTE CORONARY SYNDROMES; DUAL ANTIPLATELET THERAPY; ACUTE MYOCARDIAL-INFARCTION; DENSITY-LIPOPROTEIN CHOLESTEROL; DOUBLE-BLIND; ARTERY-DISEASE; ATRIAL-FIBRILLATION; STATIN THERAPY; LONG-TERM; CLOPIDOGREL;
D O I
10.1007/s40256-018-00322-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The COMPASS trial compared the impact of the selective direct factor Xa inhibitor, rivaroxaban, as monotherapy or in combination with aspirin on major adverse cardiovascular events (MACE) in patients with stable atherosclerotic disease. Patients treated with rivaroxaban 2.5mg twice daily in combination with aspirin experienced fewer cardiovascular events but more bleeding complications than those who received aspirin monotherapy. In contrast, a higher dose of rivaroxaban (5mg twice daily) and aspirin produced no clinical benefit and continued to be associated with greater bleeding rates than aspirin. Examining this study in the context of other trials of anticoagulant therapy in atherosclerotic vascular disease, this review attempts to place the role of very low-dose rivaroxaban in clinical context and highlights areas for future research.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 54 条
[1]   Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective [J].
Ademi, Zanfina ;
Zomer, Ella ;
Tonkin, Andrew ;
Liew, Danny .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 270 :54-59
[2]   Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial [J].
Alexander, John H. ;
Becker, Richard C. ;
Bhatt, Deepak L. ;
Cools, Frank ;
Crea, Filippo ;
Dellborg, Mikael ;
Fox, Keith A. A. ;
Goodman, Shaun G. ;
Harrington, Robert A. ;
Huber, Kurt ;
Husted, Steen ;
Lewis, Basil S. ;
Lopez-Sendon, Jose ;
Mohan, Puneet ;
Montalescot, Gilles ;
Ruda, Mikhail ;
Ruzyllo, Witold ;
Verheugt, Freek ;
Wallentin, Lars ;
Darius, Harald ;
Simoons, Maarten ;
Boersma, Eric ;
DeLemos, James ;
Spencer, Fred .
CIRCULATION, 2009, 119 (22) :2877-U39
[3]   Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].
Anand, Sonia S. ;
Bosch, Jackie ;
Eikelboom, John W. ;
Connolly, Stuart J. ;
Diaz, Rafael ;
Widimsky, Peter ;
Aboyans, Victor ;
Alings, Marco ;
Kakkar, Ajay K. ;
Keltai, Katalin ;
Maggioni, Aldo P. ;
Lewis, Basil S. ;
Stoerk, Stefan ;
Zhu, Jun ;
Lopez-Jaramillo, Patricio ;
O'Donnell, Martin ;
Commerford, Patrick J. ;
Vinereanu, Dragos ;
Pogosova, Nana ;
Ryden, Lars ;
Fox, Keith A. A. ;
Bhatt, Deepak L. ;
Misselwitz, Frank ;
Varigos, John D. ;
Vanassche, Thomas ;
Avezum, Alvaro A. ;
Chen, Edmond ;
Branch, Kelley ;
Leong, Darryl P. ;
Bangdiwala, Shrikant I. ;
Hart, Robert G. ;
Yusuf, Salim .
LANCET, 2018, 391 (10117) :219-229
[4]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[5]   Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden [J].
Begum N. ;
Stephens S. ;
Schoeman O. ;
Fraschke A. ;
Kirsch B. ;
Briere J.-B. ;
Verheugt F.W.A. ;
van Hout B.A. .
Cardiology and Therapy, 2015, 4 (2) :131-153
[6]   Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis [J].
Bhatt, Deepak L. ;
Eagle, Kim A. ;
Ohman, E. Magnus ;
Hirsch, Alan T. ;
Goto, Shinya ;
Mahoney, Elizabeth M. ;
Wilson, Peter W. F. ;
Alberts, Mark J. ;
D'Agostino, Ralph ;
Liau, Chiau-Suong ;
Mas, Jean-Louis ;
Roether, Joachim ;
Smith, Sidney C., Jr. ;
Salette, Genevieve ;
Contant, Charles F. ;
Massaro, Joseph M. ;
Steg, Ph. Gabriel .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (12) :1350-1357
[7]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[8]   Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].
Bonaca, Marc P. ;
Nault, Patrice ;
Giugliano, Robert P. ;
Keech, Anthony C. ;
Pineda, Armando Lira ;
Kanevsky, Estella ;
Kuder, Julia ;
Murphy, Sabina A. ;
Jukema, J. Wouter ;
Lewis, Basil S. ;
Tokgozoglu, Lale ;
Somaratne, Ransi ;
Sever, Peter S. ;
Pedersen, Terje R. ;
Sabatine, Marc S. .
CIRCULATION, 2018, 137 (04) :338-350
[9]   Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50) [J].
Bonaca, Marc P. ;
Gutierrez, J. Antonio ;
Creager, Mark A. ;
Scirica, Benjamin M. ;
Olin, Jeffrey ;
Murphy, Sabina A. ;
Braunwald, Eugene ;
Morrow, David A. .
CIRCULATION, 2016, 133 (10) :997-1005
[10]   Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction [J].
Bonaca, Marc P. ;
Bhatt, Deepak L. ;
Cohen, Marc ;
Steg, Philippe Gabriel ;
Storey, Robert F. ;
Jensen, Eva C. ;
Magnani, Giulia ;
Bansilal, Sameer ;
Fish, M. Polly ;
Im, Kyungah ;
Bengtsson, Olof ;
Ophuis, Ton Oude ;
Budaj, Andrzej ;
Theroux, Pierre ;
Ruda, Mikhail ;
Hamm, Christian ;
Goto, Shinya ;
Spinar, Jindrich ;
Nicolau, Jose Carlos ;
Kiss, Robert G. ;
Murphy, Sabina A. ;
Wiviott, Stephen D. ;
Held, Peter ;
Braunwald, Eugene ;
Sabatine, Marc S. ;
Morin, Suzanne ;
Dantzer, Emily ;
Acquilano, Dayle ;
McGuire, Rachael L. ;
Gannon, Joseph B. ;
Gershman, Elaine ;
Ahlbom, Ann Maxe ;
Boberg, Barbro ;
Abola, Maria Teresa ;
Ardissino, Diego ;
Aylward, Philip ;
Corbalan, Ramon ;
Dalby, Anthony ;
Diaz, Rafael ;
Hu, Dayi ;
Isaza, Daniel ;
Kamensky, Gabriel ;
Kiss, Robert ;
Kontny, Frederic ;
Lopez-Sendon, Jose ;
Medina, Felix ;
Montalescot, Gilles ;
Nicolau, Jose ;
Paolasso, Ernesto ;
Parkhomenko, Alexander .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (19) :1791-1800